Terms: = Lung cancer AND CDK6, MGC59692, 1021, Q00534, ENSG00000105810, PLSTIRE AND Treatment
111 results:
1. Postoperative ctDNA in indicating the recurrence risk and monitoring the effect of adjuvant therapy in surgical non-small cell lung cancer.
Tian X; Liu X; Wang K; Wang R; Li Y; Qian K; Wang T; Zhao X; Liu L; Zhang PL; Xiong Y; Rui J; Chen R; Zhang Y
Thorac Cancer; 2024 Apr; 15(10):797-807. PubMed ID: 38409945
[TBL] [Abstract] [Full Text] [Related]
2. MAFF confers vulnerability to cisplatin-based and ionizing radiation treatments by modulating ferroptosis and cell cycle progression in lung adenocarcinoma.
Liang J; Bi G; Huang Y; Zhao G; Sui Q; Zhang H; Bian Y; Yin J; Wang Q; Chen Z; Zhan C
Drug Resist Updat; 2024 Mar; 73():101057. PubMed ID: 38266355
[TBL] [Abstract] [Full Text] [Related]
3. Discovery of (R)-4-(8-methoxy-2-methyl-1-(1-phenylethy)-1H-imidazo[4,5-c]quinnolin-7-yl)-3,5-dimethylisoxazole as a potent and selective BET inhibitor for treatment of acute myeloid leukemia (AML) guided by FEP calculation.
Yu S; Zhang Y; Yang J; Xu H; Lan S; Zhao B; Luo M; Ma X; Zhang H; Wang S; Shen H; Zhang Y; Xu Y; Li R
Eur J Med Chem; 2024 Jan; 263():115924. PubMed ID: 37992518
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic and predictive impact of molecular tumor burden index in non-small cell lung cancer patients.
Yang F; Tang M; Cui L; Bai J; Yu J; Gao J; Nie X; Li X; Xia X; Yi X; Zhang P; Li L
Thorac Cancer; 2023 Nov; 14(31):3097-3107. PubMed ID: 37724484
[TBL] [Abstract] [Full Text] [Related]
5. Targeting FGFRs by pemigatinib induces G1 phase cell cycle arrest, cellular stress and upregulation of tumor suppressor microRNAs.
Pace A; Scirocchi F; Napoletano C; Zizzari IG; Po A; Megiorni F; Asquino A; Pontecorvi P; Rahimi H; Marchese C; Ferretti E; Nuti M; Rughetti A
J Transl Med; 2023 Sep; 21(1):626. PubMed ID: 37715207
[TBL] [Abstract] [Full Text] [Related]
6. SETD2 variation correlates with tumor mutational burden and MSI along with improved response to immunotherapy.
Zheng X; Lin J; Xiong J; Guan Y; Lan B; Li Y; Gao X; Fei Z; Chen L; Chen L; Chen L; Chen G; Guo Z; Yi X; Cao W; Ai X; Zhou C; Li X; Zhao J; Yan X; Yu Q; Si L; Chen Y; Chen C
BMC Cancer; 2023 Jul; 23(1):686. PubMed ID: 37479966
[TBL] [Abstract] [Full Text] [Related]
7. Detecting undetectable - epidemiology, etiology, and diagnosis of carcinoma of unknown primary - systematic review.
Ostojewska J; Wieczorek I; Pachciński O; Zdziennicki W; Burdan F
Folia Med Cracov; 2023 Apr; 63(1):19-37. PubMed ID: 37406274
[TBL] [Abstract] [Full Text] [Related]
8. Dexamethasone induces cancer mitigation and irreversible senescence in lung cancer cells via damaging cortical actin and sustained hyperphosphorylation of pRb.
Srivastava S; Siddiqui S; Singh S; Chowdhury S; Upadhyay V; Sethi A; Kumar Trivedi A
Steroids; 2023 Oct; 198():109269. PubMed ID: 37394085
[TBL] [Abstract] [Full Text] [Related]
9. Patlak-Ki derived from ultra-high sensitivity dynamic total body [
Wang D; Qiu B; Liu Q; Xia L; Liu S; Zheng C; Liu H; Mo Y; Zhang X; Hu Y; Zheng S; Zhou Y; Fu J; Chen N; Liu F; Zhou R; Guo J; Fan W; Liu H
Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3400-3413. PubMed ID: 37310427
[TBL] [Abstract] [Full Text] [Related]
10. Dasatinib in combination with BMS-754807 induce synergistic cytotoxicity in lung cancer cells through inhibiting lung cancer cell growth, and inducing autophagy as well as cell cycle arrest at the G1 phase.
Zhang C; Zhao X; Wang Z; Gong T; Zhao H; Zhang D; Niu Y; Li X; Zhao X; Li G; Dong X; Zhang L; Liu C; Xu J; Yu B
Invest New Drugs; 2023 Jun; 41(3):438-452. PubMed ID: 37097369
[TBL] [Abstract] [Full Text] [Related]
11. [Study on the Biological Function of Abemecilib in Inhibiting the Proliferation, Invasion and
Migration of Small Cell lung cancer with High c-Myc Expression].
Guo J; Mu D; Yu W; Sun L; Zhang J; Ren X; Han Y
Zhongguo Fei Ai Za Zhi; 2023 Feb; 26(2):105-112. PubMed ID: 36872049
[TBL] [Abstract] [Full Text] [Related]
12. Next-generation sequencing clarified why first-line treatment with osimertinib was ineffective in an autopsied case of EGFR-mutated lung squamous cell carcinoma.
Nishimura T; Fujiwara T; Fujimoto H; Tarumi H; Tsuji C; Iwanaka S; Sakakura Y; Naito M; Okugawa Y; Yasuma T; Gabazza EC; Oomoto Y; Kobayashi T; Ibata H
Thorac Cancer; 2023 Mar; 14(7):709-713. PubMed ID: 36710365
[TBL] [Abstract] [Full Text] [Related]
13. Beta-Caryophyllene Enhances the Anti-Tumor Activity of Cisplatin in lung cancer Cell Lines through Regulating Cell Cycle and Apoptosis Signaling Molecules.
Ahmed EA; Abu Zahra H; Ammar RB; Mohamed ME; Ibrahim HM
Molecules; 2022 Nov; 27(23):. PubMed ID: 36500446
[TBL] [Abstract] [Full Text] [Related]
14. High-Resolution Profiling of lung Adenocarcinoma Identifies Expression Subtypes with Specific Biomarkers and Clinically Relevant Vulnerabilities.
Roh W; Geffen Y; Cha H; Miller M; Anand S; Kim J; Heiman DI; Gainor JF; Laird PW; Cherniack AD; Ock CY; Lee SH; Getz G;
Cancer Res; 2022 Nov; 82(21):3917-3931. PubMed ID: 36040373
[TBL] [Abstract] [Full Text] [Related]
15. GPR37 promotes cancer growth by binding to cdk6 and represents a new theranostic target in lung adenocarcinoma.
Xie X; Cai X; Zhou F; Li Y; Liu Q; Cai L; Zhu W; Wei J; Jin C; Liu Z; Jiang C; Zhao H; Yang L; Zhao C; Huang X
Pharmacol Res; 2022 Sep; 183():106389. PubMed ID: 35934193
[TBL] [Abstract] [Full Text] [Related]
16. Identification of a five genes prognosis signature for triple-negative breast cancer using multi-omics methods and bioinformatics analysis.
Ma J; Chen C; Liu S; Ji J; Wu D; Huang P; Wei D; Fan Z; Ren L
Cancer Gene Ther; 2022 Nov; 29(11):1578-1589. PubMed ID: 35474355
[TBL] [Abstract] [Full Text] [Related]
17. Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial.
Fennell DA; King A; Mohammed S; Greystoke A; Anthony S; Poile C; Nusrat N; Scotland M; Bhundia V; Branson A; Brookes C; Darlison L; Dawson AG; Gaba A; Hutka M; Morgan B; Bajaj A; Richards C; Wells-Jordan P; Thomas A;
Lancet Oncol; 2022 Mar; 23(3):374-381. PubMed ID: 35157829
[TBL] [Abstract] [Full Text] [Related]
18. Co-occurrence CDK4/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung cancer.
Sitthideatphaiboon P; Teerapakpinyo C; Korphaisarn K; Leelayuwatanakul N; Pornpatrananrak N; Poungvarin N; Chantranuwat P; Shuangshoti S; Aporntewan C; Chintanapakdee W; Sriuranpong V; Vinayanuwattikun C
Sci Rep; 2022 Feb; 12(1):2167. PubMed ID: 35140316
[TBL] [Abstract] [Full Text] [Related]
19. Oncogenic circRNA C190 Promotes Non-Small Cell lung cancer via Modulation of the EGFR/ERK Pathway.
Ishola AA; Chien CS; Yang YP; Chien Y; Yarmishyn AA; Tsai PH; Chen JC; Hsu PK; Luo YH; Chen YM; Liang KH; Lan YT; Huo TI; Ma HI; Chen MT; Wang ML; Chiou SH
Cancer Res; 2022 Jan; 82(1):75-89. PubMed ID: 34753774
[TBL] [Abstract] [Full Text] [Related]
20. Schizandrin A can inhibit non‑small cell lung cancer cell proliferation by inducing cell cycle arrest, apoptosis and autophagy.
Zhu L; Wang Y; Lv W; Wu X; Sheng H; He C; Hu J
Int J Mol Med; 2021 Dec; 48(6):. PubMed ID: 34643254
[TBL] [Abstract] [Full Text] [Related]
[Next]
